ERr731 · HerWellness · hormone-free · hot-flashes · menopause · Metagenics · perimenopause · pillar-nutrition-supplements · pillar-pharmacist-product-guide · plant-based · womens-health ·May 17, 2026

Metagenics® Estrovera®: A Pharmacist’s Guide to Menopause Relief

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

The Clinical Question

What does published human clinical research establish about ERr 731® — the proprietary Siberian rhubarb root (Rheum rhaponticum L.) extract that is the sole active ingredient in Metagenics® Estrovera® — for the relief of perimenopausal and menopausal symptoms including hot flashes, night sweats, sleep disturbance, and mood changes? And how directly does that ingredient-level evidence apply to this finished product?

Bottom Line Up Front

ERr 731® has one of the more robust published evidence bases among botanical menopause supplements. The pivotal randomized, double-blind, placebo-controlled trial (Heger et al., PMID: 16894335) in 109 perimenopausal women demonstrated statistically significant reductions in the Menopause Rating Scale (MRS II) total score and all three subscales at 12 weeks versus placebo, with effects across hot flashes, sleep disturbance, mood changes, and urogenital symptoms. A separate 12-week RCT in an independent patient cohort (Kaszkin-Bettag et al., PMID: 19161045, n = 112) confirmed the primary efficacy signal. A secondary analysis of the original 109-person cohort (PMID: 17213754) additionally documented improvements in anxiety and general well-being. Long-term follow-up data from a 96-week sequential observational program (Hasper et al., PMID: 18978638) — not a randomized controlled trial — reported sustained MRS improvements and no serious safety signals through two years. The 4 mg daily dose in Estrovera® is the same nominal dose evaluated across all published trials. Important context: all published ERr 731® studies to date involve manufacturer-supported research programs; independent replication by non-affiliated investigators would further strengthen the evidence base. Manufacturer consumer surveys are not clinical trials and are not cited as evidence in this review.

What Is ERr 731®?

ERr 731® is a proprietary standardized dry extract of Siberian rhubarb root (Rheum rhaponticum L.), characterized by its stilbene glycoside content — primarily rhaponticin (2.2 mg) and desoxy-rhaponticin (1.0 mg) per 4 mg tablet. These constituents are structurally distinct from estrogen and are not classified as phytoestrogens in the traditional sense. Preclinical research has proposed serotonin receptor modulation (5-HT₂A, 5-HT₂B) as a mechanism of action, which would be consistent with effects on vasomotor thermoregulation and mood without estrogenic receptor binding. Published clinical studies did not identify clinically meaningful estrogenic effects in the measured gynecologic and safety parameters; however, this does not establish a complete absence of estrogenic biological activity, and the precise mechanism of action has not been confirmed in human pharmacodynamic studies.

What the Evidence Does — and Does Not — Establish

Evidence labels: HUMAN RCT = randomized controlled trial | OBSERVATIONAL FOLLOW-UP = non-randomized follow-on study | REVIEW = structured synthesis of published studies | PRECLINICAL = animal models or in vitro research

ERr 731® for Perimenopausal and Menopausal Symptoms

HUMAN RCT Heger M, et al. (PMID: 16894335) — Randomized, double-blind, placebo-controlled trial in 109 perimenopausal women; ERr 731® 4 mg/day versus placebo for 12 weeks; primary outcome: MRS II total score. ERr 731® produced statistically significant reductions in total MRS II score versus placebo. Improvements were observed across all three MRS subscales: somatic (hot flashes, night sweats, heart discomfort, sleep disturbance, joint and muscle discomfort), psychological (depressive mood, irritability, anxiety, mental exhaustion), and urogenital (sexual problems, bladder problems, vaginal dryness). Published gynecologic and laboratory safety parameters did not identify clinically significant estrogenic effects. The preparation was otherwise well tolerated with no clinically significant safety signals. This is the primary pivotal trial for the 4 mg dose used in Estrovera®.
HUMAN RCT Kaszkin-Bettag M, et al. (PMID: 17213754) — Secondary analysis of the same 109-person pivotal RCT cohort (PMID: 16894335), focusing specifically on anxiety and general well-being outcomes. Statistically significant improvements in anxiety and well-being measures were documented in the ERr 731® group versus placebo at 12 weeks. Note: this is a secondary outcome analysis of the same patient cohort, not an independent replication.
HUMAN RCT Kaszkin-Bettag M, et al. (PMID: 19161045) — Separate randomized, double-blind, placebo-controlled confirmatory trial in 112 perimenopausal women; ERr 731® 4 mg/day versus placebo for 12 weeks. Statistically significant improvements in total MRS score and subscales versus placebo were confirmed. This is a separate confirmatory RCT in an independent patient cohort, providing the strongest corroboration of the primary efficacy signal from the Heger trial.
OBSERVATIONAL FOLLOW-UP Hasper I, et al. (PMID: 18978638) — 96-week sequential observational follow-up program (two consecutive 48-week periods) conducted after the original RCT, in which participants continued ERr 731® 4 mg/day. MRS score improvements were sustained and continued to develop through 96 weeks. No serious adverse events were attributed to ERr 731®; monitored safety parameters remained stable throughout. Critical limitation: this was not a randomized controlled trial — it was an observational extension without a concurrent placebo arm. It provides long-term tolerability and naturalistic effectiveness data, but cannot establish controlled efficacy beyond the 12-week RCT period.
OBSERVATIONAL FOLLOW-UP Kaszkin-Bettag M, et al. (PMID: 19043936) — Open observational study in 363 perimenopausal women receiving ERr 731® in real-world clinical practice over 6 months; 252 completed the full observation period. Sustained improvements in menopausal symptom measures reported. No control group; confirms real-world use patterns and tolerability but does not constitute controlled efficacy evidence.

Manufacturer Involvement — Evidence Context
All published ERr 731® trials to date have been conducted or supported by Metagenics and its research affiliates. The trials are peer-reviewed, randomized, and placebo-controlled, and the results are consistent across multiple cohorts. However, independent replication by investigators with no financial ties to the ingredient developer would further strengthen confidence in the effect size and generalizability. This is standard evidence-evaluation practice and does not invalidate the existing trials.

What the Surveys Are — and Are Not

Metagenics references internal consumer surveys (e.g., a 2023 online survey of 424 women; a 2020 online survey of 75 women) reporting high rates of self-reported improvement. These are not clinical trials. They have no randomization, no control group, no validated blinded outcome assessment, and no peer review. They reflect consumer satisfaction, not controlled evidence of efficacy, and are not cited as clinical evidence in this review.

Serotonergic Mechanism Hypothesis

PRECLINICAL In vitro studies have identified serotonin receptor binding activity (5-HT₂A, 5-HT₂B) for rhaponticin and desoxy-rhaponticin, the principal stilbene glycosides in ERr 731®. Serotonergic pathways are involved in thermoregulatory physiology relevant to hot flash generation. Published clinical studies did not identify clinically meaningful estrogenic effects in measured safety parameters, which is consistent with a non-estrogenic mechanism. However, the human mechanistic basis for ERr 731®’s clinical effects has not been confirmed in human pharmacodynamic trials, and this does not establish a complete absence of estrogenic biological activity.

What Is Not Established

That ERr 731® is safe or effective in women with a personal history of hormone-sensitive cancers (estrogen-receptor-positive breast cancer, endometrial cancer, ovarian cancer) — this population was excluded from published trials.
That ERr 731® is equivalent in efficacy to hormone therapy — no head-to-head comparative trial has been published.
That the consumer survey percentages (83%, 90%, 4 out of 5 women) constitute clinical evidence of efficacy — these are uncontrolled self-report surveys.
That the 96-week observational data (PMID: 18978638) constitute controlled long-term efficacy evidence — the absence of a placebo arm after week 12 limits what can be concluded.
That Estrovera® as a finished commercial product has been evaluated in a published trial conducted by investigators independent of the manufacturer.
That individual patients will experience symptom onset within any specific timeframe — trial data reflect group-mean changes at 12 weeks.

Supplement Facts

Serving Size: 1 Tablet | Servings per Container: 90

Ingredient	Amount Per Serving
Rheum rhaponticum L. Root Extract (ERr 731®) Providing 2.2 mg rhaponticin and 1.0 mg desoxy-rhaponticin	4 mg

Other Ingredients: Microcrystalline cellulose, stearic acid (vegetable), croscarmellose sodium, silica, and enteric coating.

Non-GMO • Gluten-free • Vegetarian • Soy-free • Dairy-free

Finished-Product Evidence Note

Estrovera® uses the same nominal 4 mg ERr 731® dose evaluated in all published clinical trials, which means the ingredient-level evidence is more directly applicable to this product than in multi-ingredient formulas. However, the finished commercial tablet has not been independently evaluated in a published clinical trial by investigators without manufacturer affiliation. The evidence base, while stronger and more consistent than most botanical menopause supplements, originates entirely from manufacturer-supported research programs.

Pharmacist’s Note: As a PharmD, I find ERr 731® one of the more credible botanical options in the menopause-support space — not because of the marketing language around it, but because there are two separate placebo-controlled RCTs using a validated outcome instrument (MRS II), consistent results across independent patient cohorts, and a 96-week observational safety dataset that most botanical supplements simply do not have. I also want to be transparent about the full picture: all of these trials are manufacturer-supported, the 96-week follow-up was observational not randomized, and the surveys Metagenics cites prominently in its marketing materials are not clinical evidence. For women who cannot or prefer not to use hormone therapy and want a non-hormonal botanical option with a genuine RCT evidence base, this is one I am comfortable discussing. For women with a history of hormone-sensitive cancers, the published trials excluded that population — please speak with your oncologist or gynecologist before using any botanical menopause supplement. Call us at (408) 622-8068 for a pharmacist consultation.

Dosing Directions

Per current Metagenics label directions: take one tablet daily, with food or as directed by your healthcare practitioner. As an enteric-coated tablet, swallow whole — do not crush, chew, or split. The published efficacy trials used 4 mg once daily for 12 weeks of continuous use.

Safety and Precautions

Do not use if you have or develop diarrhea, loose stools, or abdominal pain — rhubarb-containing preparations may worsen these conditions. Consult your physician if you have a history of frequent diarrhea or bowel motility disorders.
Women with a personal history of hormone-sensitive cancers (estrogen-receptor-positive breast cancer, endometrial cancer, ovarian cancer) or hormone-sensitive conditions should consult their oncologist or physician before use. This population was excluded from published ERr 731® trials; safety data in this group are not available from published research.
Consult a healthcare provider before use during pregnancy or while breastfeeding. This product is not indicated during pregnancy.
Published clinical studies of ERr 731® provide limited information about drug interactions specific to this extract at the 4 mg studied dose. General rhubarb herbal interaction warnings (anticoagulants, cytochrome P450 substrates) are based on other rhubarb preparations and have not been specifically established for ERr 731®. If you take prescription medications, particularly those with a narrow therapeutic index, consult your pharmacist or physician before use.
This product is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease, including menopause or any hormone-related condition.
Keep out of reach of children. Store in a cool, dry place.

About Metagenics®

Metagenics® is a practitioner-distributed supplement brand with over 40 years in the clinical nutrition space, manufactured in GMP- and NSF-certified facilities with extensive third-party quality testing. Quality certifications address manufacturing standards — not clinical efficacy of the finished product.

Shop Women’s Health Supplements

Browse our pharmacist-curated Women’s Health collection at Khang Pharmacy →

Selected Key Studies

HUMAN RCT Heger M, et al. Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial. Menopause. 2006. PMID: 16894335. DOI: 10.1097/01.gme.0000240632.08182.e4.
n = 109 perimenopausal women; ERr 731® 4 mg/day vs. placebo, 12 weeks; primary outcome MRS II. Statistically significant reduction in total MRS II and all three subscales. Published safety parameters did not identify clinically meaningful estrogenic effects. Pivotal trial for the 4 mg dose.
HUMAN RCT Kaszkin-Bettag M, et al. The special extract ERr 731 of the roots of Rheum rhaponticum decreases anxiety and improves health state and general well-being in perimenopausal women. Menopause. 2007. PMID: 17213754.
Secondary outcome analysis of the same 109-person cohort from PMID 16894335, focusing on anxiety and general well-being. Significant improvements in ERr 731® group versus placebo. Same patient cohort as PMID 16894335 — not an independent replication.
HUMAN RCT Kaszkin-Bettag M, et al. Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms. Altern Ther Health Med. 2009. PMID: 19161045.
n = 112 perimenopausal women (56 ERr 731®, 56 placebo); 12-week RCT. Statistically significant MRS improvements confirmed. Separate confirmatory RCT in an independent patient cohort — the strongest corroboration of the primary efficacy signal.
OBSERVATIONAL FOLLOW-UP Hasper I, et al. Long-term efficacy and safety of the special extract ERr 731 of Rheum rhaponticum in perimenopausal women with menopausal symptoms. Menopause. 2009. PMID: 18978638. DOI: 10.1097/GME.0b013e3181806446.
96-week sequential observational follow-up (two 48-week periods) after the original RCT. Sustained MRS improvement; monitored safety parameters stable throughout; no serious adverse events. Not a randomized controlled trial — no placebo arm after week 12. Provides long-term tolerability data; does not establish controlled long-term efficacy.
OBSERVATIONAL FOLLOW-UP Kaszkin-Bettag M, et al. Efficacy of the special extract ERr 731 from rhapontic rhubarb for menopausal complaints: a 6-month open observational study. Altern Ther Health Med. 2008. PMID: 19043936.
n = 363 enrolled; 252 completing 6 months in real-world clinical practice. Sustained MRS improvement reported. Open observational design; no control group. Supports real-world tolerability and use patterns; does not constitute controlled efficacy evidence.

Frequently Asked Questions

How long does it take for Estrovera® to work?

The published 12-week RCTs measured statistically significant MRS score improvements at the end of 12 weeks of daily use. Some participants reported earlier improvements, but individual response timelines are not predictable from group-mean trial data. Consistent daily use at the 4 mg studied dose is important.

Is Estrovera® safe if I have or had breast cancer?

The published ERr 731® trials excluded women with a history of hormone-sensitive cancers. The available evidence does not establish safety in this population. If you have or have had estrogen-receptor-positive breast cancer, endometrial cancer, or any hormone-sensitive condition, please consult your oncologist or gynecologist before using this or any botanical menopause supplement.

Does Estrovera® contain hormones or phytoestrogens?

ERr 731® stilbene glycosides are structurally distinct from estrogen and are not classified as phytoestrogens in the traditional sense. Published clinical studies did not identify clinically meaningful estrogenic effects in the measured safety parameters. However, this does not establish a complete absence of estrogenic biological activity, and women with hormone-sensitive conditions should seek physician guidance before use.

Can I take this with my other medications?

Published clinical studies of ERr 731® provide limited specific information about drug interactions at the 4 mg studied dose. General rhubarb herbal interaction warnings are based on other rhubarb preparations and may not apply directly to ERr 731®. If you take prescription medications, particularly those with a narrow therapeutic index, consult your pharmacist or physician before starting. Call us at (408) 622-8068.

What is the Menopause Rating Scale (MRS)?

The MRS II is an 11-item validated self-rating instrument assessing menopausal symptom severity across three subscales — somatic (hot flashes, night sweats, heart discomfort, sleep disturbance, joint and muscle discomfort), psychological (depressive mood, irritability, anxiety, mental exhaustion), and urogenital (sexual problems, bladder problems, vaginal dryness). It was the primary outcome measure in the ERr 731® pivotal RCTs.

Why doesn’t this article cite Metagenics’ consumer surveys as evidence?

At Khang Pharmacy, we distinguish between controlled clinical trial evidence and consumer satisfaction surveys. The surveys cited in Metagenics’ marketing materials lack randomization, control groups, and blinded validated outcome assessment. They reflect consumer-reported experience, not controlled evidence of efficacy. We cite the published peer-reviewed RCTs as the basis for our clinical assessment.

FDA Disclaimer

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Estrovera® is a dietary supplement. The information provided in this article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Reviewed by: Dai Tran, PharmD, MBA, B.S. View full bio →